Bloki podsumowujące i pełny artykuł są po angielsku dla spójności redakcyjnej. Tytuł, opis i to wprowadzenie są zlokalizowane.

GLP-2 Analogs (Apraglutide & Glepaglutide): Beyond GLP-1 for Gut Repair

While GLP-1 drives the obesity and diabetes conversation, its incretin sibling GLP-2 (glucagon-like peptide-2) has a completely different target organ: the intestinal epithelium. GLP-2 analogs are being developed not for weight loss but for intestinal repair and short bowel syndrome (SBS) — and two next-generation analogs, apraglutide and glepaglutide, have generated compelling Phase 3 data.

GLP-1 vs GLP-2: Completely Different Biology

Both GLP-1 and GLP-2 are secreted by the same intestinal L-cells in response to meals, but they act on different receptors with different downstream effects:

GLP-2 does not cause weight loss. Its role is trophic — it promotes intestinal mucosal growth and repair.

Short Bowel Syndrome: Why GLP-2 Matters

Short bowel syndrome occurs when a significant portion of the small intestine is surgically removed or non-functional. Patients cannot absorb adequate nutrition and depend on parenteral support (PS) — intravenous nutrition — which carries significant infection risk, liver complications, and quality-of-life burden.

The therapeutic goal for GLP-2 analogs is reducing parenteral support dependency — ideally achieving "enteral autonomy" where patients can sustain nutrition orally.

The first approved GLP-2 analog, teduglutide (Gattex/Revestive), demonstrated this is achievable. Apraglutide and glepaglutide are engineered to improve on teduglutide's half-life, dosing schedule, and magnitude of effect.

Glepaglutide: Phase 3 Data (2024–2025)

Glepaglutide (Zealand Pharma) is a long-acting GLP-2 analog dosed once or twice weekly vs teduglutide's daily injection. Phase 3 results published in Gastroenterology (2024–2025):

• Statistically significant reduction in parenteral support volume vs placebo.
• Approximately 14% of patients achieved enteral autonomy (full independence from IV nutrition) — a clinically meaningful endpoint in a disease where any reduction in parenteral dependence is significant.
• Once-weekly dosing is a quality-of-life advantage over daily teduglutide.

Apraglutide: Phase 3 Data

Apraglutide (Applied Molecular Transport / Ironwood Pharmaceuticals) showed:

• Approximately 52% reduction in parenteral support volume at 52 weeks vs baseline.
• A meaningful proportion of patients achieving enteral autonomy at 52 weeks.
• Strong enough signals to support regulatory submission discussions.

Both compounds demonstrate that next-generation GLP-2 analogs can reduce dependence on parenteral nutrition in a disease with very limited therapeutic options.

Evidence Translation Context

SBS is a rare, clearly defined condition with a measurable clinical endpoint (parenteral support volume). This makes GLP-2 trial interpretation more straightforward than peptide trials with subjective or surrogate endpoints:

• Primary endpoints are functional and clinically meaningful, not just biomarkers.
• The comparator (teduglutide) already validates the mechanism — apraglutide and glepaglutide are competing on schedule and magnitude, not proving a new concept.

Who This Is Relevant For

GLP-2 analogs are a clinical, not a "biohacking," story. The relevant audience is:

• Researchers and clinicians following gastrointestinal peptide pharmacology.
• Patients with SBS or intestinal failure and their care teams.
• Peptide researchers who want to understand that the GLP family has multiple distinct therapeutic applications beyond obesity.

GLP-2 analogs are not performance or longevity peptides, and should not be framed that way.

Bottom Line

GLP-2 is the intestinal repair half of the incretin story that GLP-1 dominates. Apraglutide and glepaglutide advance what teduglutide started: less frequent dosing, stronger efficacy signals, and Phase 3 data that validates GLP-2 receptor agonism as a meaningful strategy for intestinal failure. The mechanism is clean, the endpoints are clinically grounded, and the field is moving.

Educational content only. Not medical advice.